<meta http-equiv="Content-Type" content="text/html; charset=utf-8"><link type="text/css" rel="stylesheet" href="resources/sheet.css" >
<style type="text/css">.ritz .waffle a { color: inherit; }.ritz .waffle .s0{background-color:#ffffff;text-align:left;font-weight:bold;text-decoration:underline;-webkit-text-decoration-skip:none;text-decoration-skip-ink:none;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:normal;overflow:hidden;word-wrap:break-word;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s2{background-color:#ffffff;text-align:left;font-weight:bold;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:normal;overflow:hidden;word-wrap:break-word;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s1{background-color:#ffffff;text-align:left;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:normal;overflow:hidden;word-wrap:break-word;direction:ltr;padding:2px 3px 2px 3px;}</style><div class="ritz grid-container" dir="ltr"><table class="waffle" cellspacing="0" cellpadding="0"><thead><tr><th class="row-header freezebar-origin-ltr"></th><th id="1477506350C0" style="width:920px;" class="column-headers-background">A</th><th id="1477506350C1" style="width:920px;" class="column-headers-background">B</th><th id="1477506350C2" style="width:920px;" class="column-headers-background">C</th><th id="1477506350C3" style="width:920px;" class="column-headers-background">D</th></tr></thead><tbody><tr style="height: 20px"><th id="1477506350R0" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">1</div></th><td class="s0" dir="ltr">Endometrial Hyperplasia without atypia</td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr">Source </td><td class="s1" dir="ltr">GTG 67</td></tr><tr style="height: 20px"><th id="1477506350R1" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">2</div></th><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1477506350R2" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">3</div></th><td class="s1" dir="ltr">Summary:</td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1477506350R3" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">4</div></th><td class="s1" dir="ltr">Progression to cancer &lt;5% over 20 years (1% in simple EH, 4% in complex EH)<br>Majority regress spontaneously, consider weight loss if obese and advise (if appropriate) to discontinue HRT<br>Progestogen treatment for at least 6 months - has higher disease regression rate than conservative management, advise more important if peristent hyperplasia during surveillance or if having AUB<br>IUS 1st line treatment (continuous oral progesterones alternative but regression rate lower), if effective advise to continue for 5 years as lower relapse rate, particularly if also having AUB<br>If declines IUS - advise continuous progestogen regimes like medroxyprogesterone 10–20 mg/day or norethisterone 10–15 mg/day<br>Endometrial surveillance with outpatient biopsy every 6 months<br>Once treated (ie biopsy negative), higher risk relapse patients (BMI&gt;35 and/or had oral progestogens) advise 6-monthly until 2 consecutive negative samples, then offer yearly biopsy<br>Hysterectomy may be considered especially if treatment failure<br>Endometrial ablation is not recommended<br> <br>Criteria for hyseterctomy if EH without atypia<br>(i) progression to atypical hyperplasia occurs during follow-up, or <br>(ii) there is no histological regression of hyperplasia despite 12 months of treatment, or <br>(iii) there is relapse of endometrial hyperplasia after completing progestogen treatment, or<br>(iv) there is persistence of bleeding symptoms, or <br>(v) the woman declines to undergo endometrial surveillance or comply with medical treatment.<br></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1477506350R4" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">5</div></th><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1477506350R5" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">6</div></th><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1477506350R6" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">7</div></th><td class="s2" dir="ltr">2 Types:</td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1477506350R7" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">8</div></th><td class="s1" dir="ltr">1. Hyperplasia without atypia*</td><td class="s1" dir="ltr">*traditionally hyperplasia without atypia has been further sub-classified by architecture into simple and complex.</td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1477506350R8" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">9</div></th><td class="s1" dir="ltr">2. Atypical hyperplasia</td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1477506350R9" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">10</div></th><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1477506350R10" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">11</div></th><td class="s2" dir="ltr">Major Risk Factors</td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1477506350R11" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">12</div></th><td class="s1" dir="ltr">Oestragen (HRT)</td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1477506350R12" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">13</div></th><td class="s1" dir="ltr">Tamoxifen</td><td class="s1" dir="ltr">- should have been advised IUS would lower risk of EH</td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1477506350R13" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">14</div></th><td class="s1" dir="ltr">PCOS</td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1477506350R14" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">15</div></th><td class="s1" dir="ltr">Obesity</td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1477506350R15" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">16</div></th><td class="s1" dir="ltr">Immunosuppression (transplant)</td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1477506350R16" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">17</div></th><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1477506350R17" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">18</div></th><td class="s2" dir="ltr">Hyperplasia without atypia Key Points</td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1477506350R18" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">19</div></th><td class="s1" dir="ltr">Progression to cancer &lt;5% over 20 years (1% in simple EH, 4% in complex EH)</td><td class="s1" dir="ltr">Progression to cancer &lt;5% over 20 years (1% in simple EH, 4% in complex EH)<br></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1477506350R19" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">20</div></th><td class="s1" dir="ltr">Majority regress spontaneously, consider weight loss if obese and advise (if appropriate) to discontinue HRT</td><td class="s1" dir="ltr">Majority regress spontaneously, consider weight loss if obese and advise (if appropriate) to discontinue HRT<br></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1477506350R20" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">21</div></th><td class="s1" dir="ltr">Progestogen treatment for at least 6 months - has higher disease regression rate than conservative management, advise more important if peristent hyperplasia during surveillance or if having AUB</td><td class="s1" dir="ltr">Progestogen treatment for at least 6 months - has higher disease regression rate than conservative management, advise more important if peristent hyperplasia during surveillance or if having AUB<br></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1477506350R21" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">22</div></th><td class="s1" dir="ltr">IUS 1st line treatment (continuous oral progesterones alternative but regression rate lower), if effective advise to continue for 5 years as lower relapse rate, particularly if also having AUB</td><td class="s1" dir="ltr">IUS 1st line treatment (continuous oral progesterones alternative but regression rate lower), if effective advise to continue for 5 years as lower relapse rate, particularly if also having AUB<br></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1477506350R22" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">23</div></th><td class="s1" dir="ltr">If declines IUS - advise continuous progestogen regimes like medroxyprogesterone 10–20 mg/day or norethisterone 10–15 mg/day</td><td class="s1" dir="ltr">If declines IUS - advise continuous progestogen regimes like medroxyprogesterone 10–20 mg/day or norethisterone 10–15 mg/day<br></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1477506350R23" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">24</div></th><td class="s1" dir="ltr">Endometrial surveillance with outpatient biopsy every 6 months</td><td class="s1" dir="ltr">Endometrial surveillance with outpatient biopsy every 6 months<br></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1477506350R24" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">25</div></th><td class="s1" dir="ltr">Once treated (ie biopsy negative), higher risk relapse patients (BMI&gt;35 and/or had oral progestogens) advise 6-monthly until 2 consecutive negative samples, then offer yearly biopsy</td><td class="s1" dir="ltr">Once treated (ie biopsy negative), higher risk relapse patients (BMI&gt;35 and/or had oral progestogens) advise 6-monthly until 2 consecutive negative samples, then offer yearly biopsy<br></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1477506350R25" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">26</div></th><td class="s1" dir="ltr">Hysterectomy may be considered especially if treatment failure</td><td class="s1" dir="ltr">Hysterectomy may be considered especially if treatment failure<br></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1477506350R26" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">27</div></th><td class="s1" dir="ltr">Endometrial ablation is not recommended</td><td class="s1" dir="ltr">Endometrial ablation is not recommended<br></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1477506350R27" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">28</div></th><td class="s1" dir="ltr"> </td><td class="s1" dir="ltr"> <br></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1477506350R28" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">29</div></th><td class="s2" dir="ltr">Criteria for hyseterctomy if EH without atypia</td><td class="s1" dir="ltr">Criteria for hyseterctomy if EH without atypia<br></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1477506350R29" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">30</div></th><td class="s1" dir="ltr">(i) progression to atypical hyperplasia occurs during follow-up, or </td><td class="s1" dir="ltr">(i) progression to atypical hyperplasia occurs during follow-up, or <br></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1477506350R30" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">31</div></th><td class="s1" dir="ltr">(ii) there is no histological regression of hyperplasia despite 12 months of treatment, or </td><td class="s1" dir="ltr">(ii) there is no histological regression of hyperplasia despite 12 months of treatment, or <br></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1477506350R31" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">32</div></th><td class="s1" dir="ltr">(iii) there is relapse of endometrial hyperplasia after completing progestogen treatment, or</td><td class="s1" dir="ltr">(iii) there is relapse of endometrial hyperplasia after completing progestogen treatment, or<br></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1477506350R32" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">33</div></th><td class="s1" dir="ltr">(iv) there is persistence of bleeding symptoms, or </td><td class="s1" dir="ltr">(iv) there is persistence of bleeding symptoms, or <br></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1477506350R33" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">34</div></th><td class="s1" dir="ltr">(v) the woman declines to undergo endometrial surveillance or comply with medical treatment.</td><td class="s1" dir="ltr">(v) the woman declines to undergo endometrial surveillance or comply with medical treatment.<br></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1477506350R34" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">35</div></th><td class="s2" dir="ltr"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1477506350R35" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">36</div></th><td class="s1"></td><td class="s1"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1477506350R36" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">37</div></th><td class="s2" dir="ltr">HRT</td><td class="s1"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1477506350R37" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">38</div></th><td class="s1" dir="ltr">If taking sequential HRT, advise continuous progestogen, particularly IUS</td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1477506350R38" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">39</div></th><td class="s1"></td><td class="s1"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1477506350R39" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">40</div></th><td class="s1"></td><td class="s1"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1477506350R40" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">41</div></th><td class="s2" dir="ltr">All hysterectomies (with / without atypia)</td><td class="s1"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1477506350R41" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">42</div></th><td class="s1" dir="ltr">NB: advise BSO if postmenopausal to all women having hysterectomy, offer BS if premenopausal</td><td class="s1"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1477506350R42" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">43</div></th><td class="s1" dir="ltr"></td><td class="s1"></td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1477506350R43" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">44</div></th><td class="s2" dir="ltr">Type of hyperplasia</td><td class="s2" dir="ltr">Progression Rate</td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1477506350R44" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">45</div></th><td class="s1" dir="ltr">EH without atypia (overall)</td><td class="s1" dir="ltr">&lt;5%</td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1477506350R45" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">46</div></th><td class="s1" dir="ltr">Simple EH without atypia</td><td class="s1" dir="ltr">1%</td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1477506350R46" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">47</div></th><td class="s1" dir="ltr">Complex EH without atypia</td><td class="s1" dir="ltr">4%</td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr><tr style="height: 20px"><th id="1477506350R47" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">48</div></th><td class="s1" dir="ltr">EH with atypia</td><td class="s1" dir="ltr">40%</td><td class="s1" dir="ltr"></td><td class="s1" dir="ltr"></td></tr></tbody></table></div>